Search

Per- and polyfluoroalkyl substances (PFAS) constitute a large class of toxic manmade compounds that have been used in many industrial and household products. Dispersion of PFAS in the environment has raised concerns because of their persistence and toxicity for living organisms. Both terrestrial and aquatic plants have been shown to take up PFAS from contaminated soil and groundwater, and to accumulate these compounds inside their tissues. Although PFAS generally exert a low toxicity on plants at environmentally relevant concentrations, they frequently impact biomass growth and photosynthetic activity at higher levels. Uptake, translocation, and toxicity of PFAS in plants have been well covered in literature. Although less attention has been given to the molecular mechanisms underlying the plant response to PFAS, recent studies based on -omics approaches indicate that PFAS affects the plant metabolism even a low concentration. The objective of this review is to summarize the current knowledge about the effects of PFAS on plants at the molecular level. Results from recent transcriptomics, proteomics, and metabolomics studies show that low levels of PFAS induce oxidative stress and affect multiple plant functions and processes, including photosynthesis and energy metabolism. These potentially harmful effects trigger activation of defense mechanisms. [ABSTRACT FROM AUTHOR]

Purpose: This study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular endothelial growth factor (anti-VEGF) resistant neovascular age-related macular degeneration (nAMD) in a 6-subject cohort adjunct to anti-VEGF therapy. Methods: Six eyes of six subjects with anti-VEGF resistant nAMD (persistent fluid or hemorrhage despite frequent anti-VEGF treatment) were treated with ESB between May 2018 and July 2018 as part of a larger early feasibility trial. Baseline and follow-up exams with multi-modal imaging were conducted. Results: In this analysis, six eyes were included. The mean age was 74.7 years; 33% were female; 67% had polypoidal choroidal vasculopathy. The mean number of lifetime anti-VEGF injections received prior to the study enrollment was 33.9 injections and 10 injections in the year prior to the study enrollment. In the first and second years following ESB, the mean number of injections was 8.5 and 8, respectively. No evidence of radiation-induced toxicity through 2 years following ESB was observed. The mean baseline VA was 55.3 letters. At 1 year, the mean VA increased by 3.2 letters and 1.7 letters at year 2. At 2 years, the mean change in vascular complex on ICGA was − 18%, − 43% on OCTA, and − 5% on FA. The subjects also experienced a mean decrease in CRT on OCT of 21% after 2 years. Conclusions: The results from this six-subject cohort with 2-year data support additional investigations of ESB for nAMD, specifically those with persistent disease activity and treatment resistant nAMD. [ABSTRACT FROM AUTHOR]

Social media is a tool that allows people to create and share different ideas, information and pictures/videos. It is an online way of communication to develop interaction and collaboration among people. Thus, social media might be changing the attitude and behavior of youth. It also spreads awareness among people by creating different online pages and accounts for sharing their agendas and information via these mediums. Role of social media in building the public perception is being analyzed. The study also examines the role of Facebook and Twitter in influencing political activism. It also intends to assess the level of empowerment due to awareness through social media. Survey method was used as a strategy to collect primary data. This study will enable us to understand the emerging role of social media in political activism and significant role of the online social media in political change. [ABSTRACT FROM AUTHOR]

The application of machine learning to tasks involving volumetric biomedical imaging is constrained by the limited availability of annotated datasets of three-dimensional (3D) scans for model training. Here we report a deep-learning model pre-trained on 2D scans (for which annotated data are relatively abundant) that accurately predicts disease-risk factors from 3D medical-scan modalities. The model, which we named SLIViT (for 'slice integration by vision transformer'), preprocesses a given volumetric scan into 2D images, extracts their feature map and integrates it into a single prediction. We evaluated the model in eight different learning tasks, including classification and regression for six datasets involving four volumetric imaging modalities (computed tomography, magnetic resonance imaging, optical coherence tomography and ultrasound). SLIViT consistently outperformed domain-specific state-of-the-art models and was typically as accurate as clinical specialists who had spent considerable time manually annotating the analysed scans. Automating diagnosis tasks involving volumetric scans may save valuable clinician hours, reduce data acquisition costs and duration, and help expedite medical research and clinical applications., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)

Purpose: Compare choroidal changes in ranibizumab versus panretinal photocoagulation (PRP)-treated eyes with proliferative diabetic retinopathy (PDR)., Methods: DRCR Retina Network Protocol S post hoc analysis evaluated optical coherence tomography change in choroidal thickness (subfoveal and 3mm superior and inferior to the fovea) through five years; choroidal vascularity index (CVI) was assessed at baseline and one year. Mixed linear models for choroidal change included adjustments for the baseline choroidal value and age., Results: This study included 328 eyes (158 ranibizumab and 170 PRP) from 256 participants (88 ranibizumab and 95 PRP eyes at five years). Mean change in choroidal thickness from baseline to five years at the fovea was -12 µm in ranibizumab versus -8 µm in PRP (difference [95% confidence interval]: -4 [-18 to 10], P = 0.57), superior was -14 µm versus -19 µm (difference: 5 [-8 to 17], P = 0.45) and inferior was -26 µm versus -32 µm [difference: 5 (-9 to 20), P = 0.45]; change at all three points within the ranibizumab group, and the superior and inferior points for PRP, were statistically significant (P < .05). Mean change in CVI at one year was -0.02% in ranibizumab versus -0.95% in PRP (difference: 0.93 [-0.35 to 2.21], P = 0.14)., Conclusions: In patients with PDR, treatment with ranibizumab versus PRP did not result in statistically significant differences in five-year choroidal thickness or one-year CVI change. Both groups had significant decreases in choroidal thickness at five years., Translational Relevance: Ranibizumab treatment for PDR did not statistically significantly affect choroidal thickness or vascularity differently than PRP.